Biomea Fusion Inc
NASDAQ:BMEA
Intrinsic Value
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancer... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BMEA.
Biomea Fusion Inc's market capitalization is 393.8m USD.
BMEA stock price is 10.98 USD.
BMEA.
BMEA. Open DCF Valuation
BMEA. Open Relative Valuation
BMEA has upside potential of 406% compared to the average analyst price target.
Open Wall St Estimates
BMEA has negative Free Cash Flow for the last twelve months.
BMEA has negative Operating Income for the last twelve months.
BMEA has negative Net Income for the last twelve months.
BMEA's ROE (Return on Equity) has significantly decreased in the last 3 years from -19% to -84%, and is approaching profitability.
BMEA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -81% to -985%, and is approaching profitability.
BMEA's ROE (Return on Equity) for the past 12 months is negative and is equal to -84%.
BMEA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -985%.
BMEA has negative three-year average ROE (Return on Equity): -41%. The company is not efficient at transforming stockholders' equity into net income.
BMEA has negative three-year average ROIC (Return on Invested Capital): -522%. The company is not efficient at using invested capital to generate operating income.
BMEA's short-term assets (179m USD) exceed its short-term liabilties (23m USD).
BMEA's long-term assets (200m USD) exceed its long-term liabilties (31m USD).
BMEA's D/E (Debt to Equity) is very low and is equal to 0.
BMEA's Altman Z-Score is very high and is equal to 6.23.
Fundamental Analysis
Biomea Fusion Inc
Balance Sheet Decomposition
Biomea Fusion Inc
| Current Assets | 179.2m |
| Cash & Short-Term Investments | 176.9m |
| Other Current Assets | 2.3m |
| Non-Current Assets | 20.7m |
| PP&E | 14.9m |
| Other Non-Current Assets | 5.9m |
| Current Liabilities | 22.9m |
| Accounts Payable | 6.9m |
| Accrued Liabilities | 15.8m |
| Other Current Liabilities | 192k |
| Non-Current Liabilities | 7.8m |
| Other Non-Current Liabilities | 7.8m |
Earnings Waterfall
Biomea Fusion Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-126.1m
USD
|
|
Operating Income
|
-126.1m
USD
|
|
Other Expenses
|
8.9m
USD
|
|
Net Income
|
-117.3m
USD
|
Free Cash Flow Analysis
Biomea Fusion Inc
BMEA Profitability Score
Profitability Due Diligence
Biomea Fusion Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Biomea Fusion Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
BMEA Solvency Score
Solvency Due Diligence
Biomea Fusion Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Biomea Fusion Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMEA Price Targets Summary
Biomea Fusion Inc
According to Wall Street analysts, the average 1-year price target for
BMEA
is 55.52 USD
with a low forecast of 30.3 USD and a high forecast of 94.5 USD.
Ownership
BMEA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BMEA Price
Biomea Fusion Inc
| Average Annual Return | -25.06% |
| Standard Deviation of Annual Returns | 35.44% |
| Max Drawdown | -86% |
| Market Capitalization | 393.8m USD |
| Shares Outstanding | 35 889 400 |
| Percentage of Shares Shorted | 67.59% |
BMEA News
Last Important Events
Biomea Fusion Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Biomea Fusion Inc
Company Profile
Biomea Fusion Inc
Country
Industry
Market Cap
Dividend Yield
Description
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.
You don't have any saved screeners yet
